Previous 10 | Next 10 |
home / stock / cprx / cprx articles
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenu...
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, pat...
CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-ce...
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results ...
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning. The company announced the pricing of a p...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Shares of Franklin Covey Co. (NYSE: FC...
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a t...
A substantial insider sell was reported on December 19, by Molly Harper, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX), based on the recen...
It was reported on December 14, that David S Tierney, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX) executed a significant insider sell, a...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...